Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016.
Identifieur interne : 000042 ( Main/Corpus ); précédent : 000041; suivant : 000043Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016.
Auteurs : A. Möhl ; L. Gr Fe ; C. Helmeke ; D. Ziehm ; M. Monazahian ; H-M Irmscher ; J. DreesmanSource :
- Epidemiology and infection [ 1469-4409 ] ; 2018.
English descriptors
- KwdEn :
- Adolescent, Child, Child, Preschool, Female, Germany, Humans, Infant, Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H3N2 Subtype (immunology), Influenza B virus (immunology), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (prevention & control), Logistic Models, Male, Seasons, Sentinel Surveillance.
- MESH :
- chemical , immunology : Influenza Vaccines.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- prevention & control : Influenza, Human.
- chemical , therapeutic use : Influenza Vaccines.
- Adolescent, Child, Child, Preschool, Female, Germany, Humans, Infant, Logistic Models, Male, Seasons, Sentinel Surveillance.
Abstract
Influenza vaccine effectiveness (VE) has to be estimated anew for every season to explore vaccines' protective effect in the population. We report VE estimates against laboratory-confirmed influenza A(H1N1)pdm09, A(H3N2) and influenza B among children aged 2-17 years, using test-negative design. Pooled data from two German federal states' surveillance systems for acute respiratory illness from week 40/2012 to 20/2016 was used, yielding a total of 10 627 specimens. Odds ratios and 95% confidence intervals (95% CIs) for the association between laboratory-confirmed influenza and vaccination status were calculated by multivariate logistic regression adjusting for age, sex, illness onset and federal state. VE was estimated as 1-Odds Ratio. Overall adjusted VE was 33% (95% CI: 24·3-40·7). A strong variation of VE between the seasons and subtypes was observed: highest season- and subtype-specific VE of 86·2% (95% CI: 41·3-96·7) was found against A(H1N1)pdm09 in 7-17-year-olds in 2015/16. Low estimates of VE were observed against A(H3N2) in any season, e.g. 1·5% (95% CI: -39·3-30·3) in 2014/15. Estimates showed a tendency to higher VE among 7-17-year-old children, but differences were not statistically significant. Although our findings are common in studies estimating influenza VE, we discussed several explanations for observed low VE.
DOI: 10.1017/S0950268817002709
PubMed: 29208075
Links to Exploration step
pubmed:29208075Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016.</title><author><name sortKey="Mohl, A" sort="Mohl, A" uniqKey="Mohl A" first="A" last="Möhl">A. Möhl</name><affiliation><nlm:affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gr Fe, L" sort="Gr Fe, L" uniqKey="Gr Fe L" first="L" last="Gr Fe">L. Gr Fe</name><affiliation><nlm:affiliation>State Agency for Consumer Protection of Saxony-Anhalt,Magdeburg,Saxony-Anhalt,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Helmeke, C" sort="Helmeke, C" uniqKey="Helmeke C" first="C" last="Helmeke">C. Helmeke</name><affiliation><nlm:affiliation>State Agency for Consumer Protection of Saxony-Anhalt,Magdeburg,Saxony-Anhalt,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ziehm, D" sort="Ziehm, D" uniqKey="Ziehm D" first="D" last="Ziehm">D. Ziehm</name><affiliation><nlm:affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Monazahian, M" sort="Monazahian, M" uniqKey="Monazahian M" first="M" last="Monazahian">M. Monazahian</name><affiliation><nlm:affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Irmscher, H M" sort="Irmscher, H M" uniqKey="Irmscher H" first="H-M" last="Irmscher">H-M Irmscher</name><affiliation><nlm:affiliation>State Agency for Consumer Protection of Saxony-Anhalt,Magdeburg,Saxony-Anhalt,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Dreesman, J" sort="Dreesman, J" uniqKey="Dreesman J" first="J" last="Dreesman">J. Dreesman</name><affiliation><nlm:affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29208075</idno><idno type="pmid">29208075</idno><idno type="doi">10.1017/S0950268817002709</idno><idno type="wicri:Area/Main/Corpus">000042</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000042</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016.</title><author><name sortKey="Mohl, A" sort="Mohl, A" uniqKey="Mohl A" first="A" last="Möhl">A. Möhl</name><affiliation><nlm:affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gr Fe, L" sort="Gr Fe, L" uniqKey="Gr Fe L" first="L" last="Gr Fe">L. Gr Fe</name><affiliation><nlm:affiliation>State Agency for Consumer Protection of Saxony-Anhalt,Magdeburg,Saxony-Anhalt,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Helmeke, C" sort="Helmeke, C" uniqKey="Helmeke C" first="C" last="Helmeke">C. Helmeke</name><affiliation><nlm:affiliation>State Agency for Consumer Protection of Saxony-Anhalt,Magdeburg,Saxony-Anhalt,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ziehm, D" sort="Ziehm, D" uniqKey="Ziehm D" first="D" last="Ziehm">D. Ziehm</name><affiliation><nlm:affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Monazahian, M" sort="Monazahian, M" uniqKey="Monazahian M" first="M" last="Monazahian">M. Monazahian</name><affiliation><nlm:affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Irmscher, H M" sort="Irmscher, H M" uniqKey="Irmscher H" first="H-M" last="Irmscher">H-M Irmscher</name><affiliation><nlm:affiliation>State Agency for Consumer Protection of Saxony-Anhalt,Magdeburg,Saxony-Anhalt,Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Dreesman, J" sort="Dreesman, J" uniqKey="Dreesman J" first="J" last="Dreesman">J. Dreesman</name><affiliation><nlm:affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Epidemiology and infection</title><idno type="eISSN">1469-4409</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Germany</term><term>Humans</term><term>Infant</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza A Virus, H3N2 Subtype (immunology)</term><term>Influenza B virus (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (prevention & control)</term><term>Logistic Models</term><term>Male</term><term>Seasons</term><term>Sentinel Surveillance</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H3N2 Subtype</term><term>Influenza B virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Germany</term><term>Humans</term><term>Infant</term><term>Logistic Models</term><term>Male</term><term>Seasons</term><term>Sentinel Surveillance</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza vaccine effectiveness (VE) has to be estimated anew for every season to explore vaccines' protective effect in the population. We report VE estimates against laboratory-confirmed influenza A(H1N1)pdm09, A(H3N2) and influenza B among children aged 2-17 years, using test-negative design. Pooled data from two German federal states' surveillance systems for acute respiratory illness from week 40/2012 to 20/2016 was used, yielding a total of 10 627 specimens. Odds ratios and 95% confidence intervals (95% CIs) for the association between laboratory-confirmed influenza and vaccination status were calculated by multivariate logistic regression adjusting for age, sex, illness onset and federal state. VE was estimated as 1-Odds Ratio. Overall adjusted VE was 33% (95% CI: 24·3-40·7). A strong variation of VE between the seasons and subtypes was observed: highest season- and subtype-specific VE of 86·2% (95% CI: 41·3-96·7) was found against A(H1N1)pdm09 in 7-17-year-olds in 2015/16. Low estimates of VE were observed against A(H3N2) in any season, e.g. 1·5% (95% CI: -39·3-30·3) in 2014/15. Estimates showed a tendency to higher VE among 7-17-year-old children, but differences were not statistically significant. Although our findings are common in studies estimating influenza VE, we discussed several explanations for observed low VE.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29208075</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>01</Month></PubDate></JournalIssue><Title>Epidemiology and infection</Title><ISOAbbreviation>Epidemiol. Infect.</ISOAbbreviation></Journal><ArticleTitle>Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016.</ArticleTitle><Pagination><MedlinePgn>78-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0950268817002709</ELocationID><Abstract><AbstractText>Influenza vaccine effectiveness (VE) has to be estimated anew for every season to explore vaccines' protective effect in the population. We report VE estimates against laboratory-confirmed influenza A(H1N1)pdm09, A(H3N2) and influenza B among children aged 2-17 years, using test-negative design. Pooled data from two German federal states' surveillance systems for acute respiratory illness from week 40/2012 to 20/2016 was used, yielding a total of 10 627 specimens. Odds ratios and 95% confidence intervals (95% CIs) for the association between laboratory-confirmed influenza and vaccination status were calculated by multivariate logistic regression adjusting for age, sex, illness onset and federal state. VE was estimated as 1-Odds Ratio. Overall adjusted VE was 33% (95% CI: 24·3-40·7). A strong variation of VE between the seasons and subtypes was observed: highest season- and subtype-specific VE of 86·2% (95% CI: 41·3-96·7) was found against A(H1N1)pdm09 in 7-17-year-olds in 2015/16. Low estimates of VE were observed against A(H3N2) in any season, e.g. 1·5% (95% CI: -39·3-30·3) in 2014/15. Estimates showed a tendency to higher VE among 7-17-year-old children, but differences were not statistically significant. Although our findings are common in studies estimating influenza VE, we discussed several explanations for observed low VE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Möhl</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gräfe</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Agency for Consumer Protection of Saxony-Anhalt,Magdeburg,Saxony-Anhalt,Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helmeke</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Agency for Consumer Protection of Saxony-Anhalt,Magdeburg,Saxony-Anhalt,Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziehm</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monazahian</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irmscher</LastName><ForeName>H-M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>State Agency for Consumer Protection of Saxony-Anhalt,Magdeburg,Saxony-Anhalt,Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dreesman</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Governmental Institute of Public Health of Lower Saxony,Hannover,Lower Saxony,Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Epidemiol Infect</MedlineTA><NlmUniqueID>8703737</NlmUniqueID><ISSNLinking>0950-2688</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Epidemiology</Keyword><Keyword MajorTopicYN="Y">influenza (seasonal)</Keyword><Keyword MajorTopicYN="Y">routine surveillance data</Keyword><Keyword MajorTopicYN="Y">test-negative design</Keyword><Keyword MajorTopicYN="Y">vaccine effectiveness</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29208075</ArticleId><ArticleId IdType="pii">S0950268817002709</ArticleId><ArticleId IdType="doi">10.1017/S0950268817002709</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000042 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000042 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:29208075
|texte= Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:29208075" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |